Bradner James E. 4

What Happened
James E. Bradner, Executive Vice President, Research and Development at Amgen, had 446 shares disposed on May 7, 2026 to satisfy a tax liability (transaction code F). The shares were valued at $331.11 each for a total of approximately $147,675. This was a routine tax-withholding transaction tied to equity awards rather than an open-market sale intended as a personal cash-out.

Key Details

• Transaction date and price: May 7, 2026 — 446 shares at $331.11 each, total ≈ $147,675.
• Transaction type: F (payment of exercise price or tax liability — shares withheld/disposed to cover taxes).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The filing notes 1,273 Dividend Equivalents (DEs) were credited to unvested Restricted Stock Units under Amgen’s equity plan; DEs are paid out in shares on a one-to-one basis per the vesting schedule, with cash for fractional shares.
• Filing: Form 4 filed May 11, 2026 — the filing date is within the typical two-business-day window following the May 7 transaction (timely).

Context
This was a tax-withholding action related to equity compensation (DEs/RSUs), a common administrative step when awards vest. Such withholdings are routine and do not necessarily indicate insider sentiment about the company’s stock.